EC Number |
Inhibitors |
Structure |
---|
2.7.11.23 | (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetamide |
i.e. CPI203, phosphorylation of the CTD Ser2 is inhibited in vivo by a BRD4 inhibitor that blocks its binding to chromatin |
|
2.7.11.23 | (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate |
i.e. JQ1 |
|
2.7.11.23 | 1-(5-isoquinolinesulfonyl)-2-methylpiperazine |
i.e. H7, CTD kinase inhibitor |
|
2.7.11.23 | 1-(5-isoquinolinesulfonyl)-2-methylpiperazine |
i.e. H7, CTD kinase inhibitor, blocks mRNA elongation in vivo, but does not affect U2 snRNA transcription |
|
2.7.11.23 | 1-NA-PP1 |
potent inhibitor of Kin28as allele kinase activity, Kin28as inhibition reduces transcript capping, overview, but inhibition of Kin28 does not inhibit transcription |
|
2.7.11.23 | 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole |
nucleotide analog |
|
2.7.11.23 | 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole |
inhibits the CTD kinase |
|
2.7.11.23 | 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole |
CTD kinase inhibitor, blocks mRNA elongation in vivo, but does not affect U2 snRNA transcription |
|
2.7.11.23 | 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole |
CDK9 inhibitor, inhibits transcriptional activation by EBNA 2, potential anti-Epstein-Barr virus agent |
|
2.7.11.23 | 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole |
- |
|